<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02757846</url>
  </required_header>
  <id_info>
    <org_study_id>20160427ABCD</org_study_id>
    <nct_id>NCT02757846</nct_id>
  </id_info>
  <brief_title>Radiomics of Hepatocellular Carcinoma</brief_title>
  <official_title>Quantitative Imaging for Evaluation of Response to Cancer Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eastern Hepatobiliary Surgery Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Province People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We propose a radiomics approach to identify prognostic biomarkers of HCC and provide patients
      with some reasonable advice for their therapies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radiomics is emerging fields that is based on quantitative analysis of medical images.
      Tri-phasic CT images are currently the standard imaging modality for the management of HCC.
      Our goal is to improve treatment decisions of HCC patients through better understanding of
      their prognosis based on radiomics modeling of HCC. Radiomics is defined as the extraction of
      quantitative image features from medical images. We will use triphasic CT data of at least
      200 patients and develop a robust strategy to extract imaging features from CT. We will use
      deep learning in the form of a Convolutional Neural Network to segment HCC lesions and use
      image feature extraction algorithms with supervised classification to predict prognosis.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>April 2017</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>quantitative image features extracted from CT images can be used as imaging marker for prognosis</measure>
    <time_frame>five(year)</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Currently, a cohort of 20 patients has already been collected from the collaborating
        hospitals. Next, the 5 hospitals will collect at least 1200 patients within 1-2 years and
        up to 6000 patients during the full course of the project (5 years).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The purpuse of our research is to improve treatment ,therefore we have no creteria.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>di dong, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Key laboratory of molecular imaging Chinese Academy of Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Key Laboratory of Molecular Imaging, Chinese Academy of Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100190</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.mitk.net/</url>
    <description>A Website from Key Laboratory of Molecular Imaging, Chinese Academy of Sciences</description>
  </link>
  <reference>
    <citation>Shen W, Zhou M, Yang F, Yang C, Tian J. Multi-scale Convolutional Neural Networks for Lung Nodule Classification. Inf Process Med Imaging. 2015;24:588-99.</citation>
    <PMID>26221705</PMID>
  </reference>
  <reference>
    <citation>Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010 Jun 15;26(12):1572-3. doi: 10.1093/bioinformatics/btq170. Epub 2010 Apr 28.</citation>
    <PMID>20427518</PMID>
  </reference>
  <reference>
    <citation>Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K, Hoang-Xuan K, Delattre JY. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009 Sep 1;27(25):4150-4. doi: 10.1200/JCO.2009.21.9832. Epub 2009 Jul 27.</citation>
    <PMID>19636000</PMID>
  </reference>
  <reference>
    <citation>Cui Y, Jia J. Update on epidemiology of hepatitis B and C in China. J Gastroenterol Hepatol. 2013 Aug;28 Suppl 1:7-10. doi: 10.1111/jgh.12220. Review.</citation>
    <PMID>23855289</PMID>
  </reference>
  <reference>
    <citation>Zhu F, Shi Z, Qin C, Tao L, Liu X, Xu F, Zhang L, Song Y, Liu X, Zhang J, Han B, Zhang P, Chen Y. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36. doi: 10.1093/nar/gkr797. Epub 2011 Sep 24.</citation>
    <PMID>21948793</PMID>
  </reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2016</study_first_submitted>
  <study_first_submitted_qc>April 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2016</study_first_posted>
  <last_update_submitted>April 28, 2016</last_update_submitted>
  <last_update_submitted_qc>April 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Sciences</investigator_affiliation>
    <investigator_full_name>Chongwei Chi, Ph.D</investigator_full_name>
    <investigator_title>Quantitative Imaging for Evaluation of Response to Cancer Therapies</investigator_title>
  </responsible_party>
  <keyword>Radiomics</keyword>
  <keyword>prognosis</keyword>
  <keyword>medical images</keyword>
  <keyword>Hepatocellular carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

